{
  "id": 184063,
  "title": "First-in-class small molecule inhibitor shows promise against pancreatic cancer in preclinical studies",
  "url": "https://urgent.news/2026/08/05/first-in-class-small-molecule-inhibitor-shows-promise-against",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-05T17:20:08.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-class-small-molecule-inhibitor-pancreatic.html"
  },
  "original_language": "en",
  "account": "Researchers at Mayo Clinic have developed an experimental drug, aided by artificial intelligence, to target the PDZ domain of the GIPC1 protein, which is involved in the growth and resistance to treatment of various cancers, including pancreatic cancer. In laboratory studies, the drug demonstrated the ability to slow down tumor growth, improve survival rates, and enhance the effectiveness of the chemotherapy drug gemcitabine. These findings, published in Cell Reports, also highlight how AI can aid in the development of small-molecule inhibitors for target proteins, potentially reducing toxicity and accelerating the discovery of new cancer treatments. Pancreatic cancer remains challenging to treat due to its often late diagnosis and resistance to many existing therapies. However, this study represents a promising advance, offering a new strategy for targeting the disease. The AI-driven discovery process involved screening nearly 40,000 potential compounds before identifying one that effectively blocks the GIPC1 protein. While the experimental drug showed early signs of altering the tumor microenvironment, further research is required to assess its safety and determine if it can progress to clinical trials. Debabrata (Dev) Mukhopadhyay, Ph.D., the senior author of the study and a cancer researcher at Mayo Clinic in Florida, emphasized that this work demonstrates AI's potential in identifying new therapeutic opportunities for targets previously considered undruggable.",
  "summary": "Mayo Clinic researchers have developed an experimental drug with the help of artificial intelligence (AI) to target the \"undruggable\" PDZ domain of the GIPC1 protein, which helps different types of cancer, including pancreatic cancer, grow and resist treatment. In laboratory studies, the drug slowed tumor growth, improved survival and enhanced the effects of the chemotherapy drug gemcitabine.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}